FATE THERAPEUTICS INC (FATE) Stock Profile — Insider Trades & Financials

Revenue$1.4M

Net Income-$32.4M

EPS$-1.15

Market Cap$137.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Bahram Valamehr

CEO & Executive Director

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The companyâs chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Founded: 2007
Employees: 161

⚡

Core Efficiency

ROE?

-15.63%

ROA?

-10.15%

Op. Margin?

-2536.23%

📊

Profitability Ratios

Net Margin?

-2364.79%

Current Ratio?

5.79

Loading company sections...

FATE THERAPEUTICS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness